Takeda files for vedolizumab approval in Japan

23 August 2017
2019_biotech_test_vial_discovery_big

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) has submitted a New Drug Application to the Ministry of Health, Labor and Welfare in Japan for the investigational humanized monoclonal antibody vedolizumab (development code: MLN0002) for the treatment of adults with moderately to severely active ulcerative colitis (UC).

The NDA filing included data from Study CCT-101, a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase III study investigating the efficacy, safety and pharmacokinetics of vedolizumab induction and maintenance treatment involving 292 Japanese patients with moderate or severe UC. Results from Study CCT-101 will be presented at scientific meeting in the future. The NDA filing also included data from the international, randomized, double blind, placebo-controlled GEMINI I pivotal Phase III study of vedolizumab induction and maintenance treatment involving 895 patients with moderate to severe UC.

“UC is a chronic, progressive inflammatory disease of the large intestine, which typically affects young adults. The disease has a high impact on their quality of life with symptoms including diarrhea, rectal bleeding, incontinence and abdominal pain,” said Toshiro Heya, head of Takeda Development Center Japan. “Through this submission, we may provide an alternative treatment option to the increasing number of people with UC in Japan.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology